The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) will jointly host a virtual meeting on April 9 to build on efforts to broaden eligibility criteria to make clinical trials more representative.
The ASCO-Friends event, Modernizing Eligibility Criteria in Clinical Trials: How We Can Improve Patient Access and Representation, will bring together experts from across the healthcare sector to discuss the recent release of new ASCO-Friends recommendations for modernizing eligibility criteria.
An opening keynote will feature a discussion with Ned Sharpless, MD, Director of the National Cancer Institute (NCI) and Janet Woodcock, MD, Acting Commissioner of the U.S. Food and Drug Administration (FDA). Ed Kim, MD, MBA, Co-Chair of the ASCO-Friends Task Force on Broadening Cancer Clinical Trial Eligibility Criteria, will serve as moderator.
The joint recommendations, which are detailed in a series of articles published in Clinical Cancer Research, a journal of the American Association for Cancer Research, provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
Keynotes and panels will discuss how overly restrictive eligibility criteria can impact patient access to trials, trial accrual rates, and limit the ability to generalize the results to the broader population of patients who will ultimately use the drug.
Modernizing Eligibility Criteria in Clinical Trials: How We Can Improve Patient Access and Representation
Friday, April 9, 2021
1:00PM EDT - 2:00PM EDT
Stay connected to ASCO in Action for updates on cancer research and policy issues.